Inflammation and Late-Life Depressive Symptoms: Inflammation et symptômes dépressifs chez les personnes âgées
Background Low-level systemic inflammation has been associated with late-life depressive symptoms. Whether individuals with higher inflammation derive preventive benefit from low-dose aspirin therapy is unknown. Methods We performed a post-hoc analysis of the ASPirin in Reducing Events in the Elderly (ASPREE) randomized, double-blind, placebo-controlled trial. Baseline high-sensitivity C-reactive protein (hsCRP) was measured in plasma and depressive symptoms were assessed annually using the Center for Epidemiologic Studies Depression 10 Scale (CES-D-10), with elevated symptoms defined as CES-D-10 ≥ 8. Participants with elevated depressive symptoms at baseline were excluded. We fitted population-averaged logistic generalized estimating equation models adjusted for baseline sociodemographic and lifestyle covariates, including an hsCRP × treatment interaction to test effect modification by aspirin. Results Higher baseline hsCRP was associated with increased odds of elevated depressive symptoms during follow-up (OR 1.07 per SD increase in hsCRP, 95% CI 1.03–1.11). Low-dose aspirin allocation did not modify the hsCRP-depressive symptoms association (interaction OR 1.02, 95% CI 0.94–1.10). Findings were similar after additional adjustment for comorbidity and other covariates. Conclusions In community-dwelling older adults during the ASPREE randomized trial period, higher baseline hsCRP was modestly associated with elevated depressive symptoms. There was no evidence that low-dose aspirin was associated with reduced risk of depressive symptoms among participants with higher baseline inflammation.
Authors
- Paul A Lacaze (ORCID: https://orcid.org/0000-0002-0902-6798)
- Belayneh Mengist (ORCID: https://orcid.org/0000-0002-0363-8777)
- Chenglong Yu (ORCID: https://orcid.org/0000-0002-0546-2779)
- Mohammadreza Mohebbi (ORCID: https://orcid.org/0000-0001-9713-7211)
- Malcolm Forbes (ORCID: https://orcid.org/0000-0002-8339-6471)
- Matthew JY Kang (ORCID: https://orcid.org/0000-0001-9375-3762)
- John J. McNeil (ORCID: https://orcid.org/0000-0002-1049-5129)
- Mojtaba Lotfaliany (ORCID: https://orcid.org/0000-0001-6594-9004)
- A.M. Isvoranu
- T L Nguyen (ORCID: https://orcid.org/0000-0001-8378-555X)
- Robyn Woods (ORCID: https://orcid.org/0000-0003-1249-6149)
- J E Neumann (ORCID: https://orcid.org/0000-0002-9478-2757)
Institutions
- The Royal Melbourne Hospital (AU)
- Barwon Health (AU)
- Deakin University (AU)
- Universität Hamburg (DE)
- The University of Melbourne (AU)
- National University of Singapore (SG)
- Monash University (AU)
Publication Details
- Journal
- The Canadian Journal of Psychiatry
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1177/07067437261500819
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Monash University
- National Institutes of Health
- Medical Research Council
- National Health and Medical Research Council
- National Institute on Aging
- National Cancer Institute